• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.
【24h】

The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.

机译：异体干细胞移植后单克隆抗体在移植物抗宿主病治疗中的应用。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Graft-versus-host disease (GVHD) remains the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Steroids along with calcineurin inhibitors remain the standard initial therapy, however, less than half of the patients completely respond and there is no uniformly accepted therapy for patients with steroid-resistant GVHD. AREAS COVERED: This paper reviews the current role and ongoing development of mAbs in the treatment of GVHD. Various mAbs to cell surface antigens on GVHD effector cells have been investigated for the treatment of acute GVHD: these include anti-TNF-alpha antibodies, IL-2 receptor antagonists, anti-CD3 and anti-CD52 mAbs, while anti-CD20 mAb has been extensively investigated in the setting of chronic GVHD. Overall, response rates have been reported to be greater than 60%, although it should be emphasized that the long-term survival still remains suboptimal, mainly due to the detrimental side effects of infectious complications, progressive GVHD and relapse of underlying malignancy. EXPERT OPINION: Future challenges will include more appropriate definition of these agents in the therapeutic scenario of GVHD. Combinations of mAbs or mAb combined with newer immunosuppressive drugs might potentially achieve greater success, especially if used early in the disease process.
机译：简介：异体造血干细胞移植（HSCT）后，移植物抗宿主病（GVHD）仍然是发病率和死亡率的主要原因。类固醇与钙调神经磷酸酶抑制剂仍然是标准的初始治疗方法，但是，只有不到一半的患者完全缓解，并且对于类固醇耐药的GVHD患者没有统一的治疗方法。涵盖的领域：本文回顾了单克隆抗体在GVHD治疗中的当前作用和持续发展。已经研究了针对GVHD效应细胞上细胞表面抗原的各种mAb，用于治疗急性GVHD：包括抗TNF-α抗体，IL-2受体拮抗剂，抗CD3和抗CD52 mAb，而抗CD20 mAb具有在慢性GVHD的背景下进行了广泛的研究。总体而言，据报道缓解率大于60％，尽管应强调的是长期存活率仍然不理想，这主要是由于感染并发症，进行性GVHD恶化和潜在恶性肿瘤复发的不利影响。专家意见：未来的挑战将包括在GVHD的治疗方案中更恰当地定义这些药物。 mAb或mAb与较新的免疫抑制药物联合使用可能会取得更大的成功，特别是如果在疾病过程的早期使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号